60 Degrees Pharmaceuticals Equity Warrants Exp 16 May 2028 Warrant(SXTPW)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

SXTPW 60 Degrees Pharmaceuticals Equity Warrants Exp 16 May 2028 Warrant

已收盘 11-11 16:00:00 EST

0.0294

+0.0031

+11.79%

最高0.0294	最低0.0294	成交量992.00
今开0.0294	昨收0.0263	日振幅0.00%
总市值12.07万	流通市值12.07万	总股本410.45万
成交额29.00	换手率0.02%	流通股本410.45万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"SXTPW","market":"US","secType":"STK","nameCN":"60 Degrees Pharmaceuticals Equity Warrants Exp 16 May 2028 Warrant","latestPrice":0.0294,"timestamp":1794430800000,"preClose":0.0263,"halted":0,"volume":992,"delay":0,"changeRate":0.11787072243346002,"floatShares":4104469,"shares":4104469,"eps":0,"marketStatus":"已收盘","change":0.0031,"latestTime":"11-11 16:00:00 EST","open":0.0294,"high":0.0294,"low":0.0294,"amount":29,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1794474000000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":0.0263,"volumeRatio":0.417684},"requestUrl":"/m/hq/s/SXTPW","defaultTab":"news","newsList":[{"id":"1180936305","title":"60 Degrees Pharmaceuticals宣布住院巴贝斯虫病研究达到最低入组人数；中期数据解读计划于2026年10月6日前公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1180936305","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180936305?lang=zh_cn&edition=full","pubTime":"2026-07-30 04:05","pubTimestamp":1785355520,"startTime":"0","endTime":"0","summary":"60 Degrees Pharmaceuticals, Inc. 今日对外公布，其针对住院巴贝斯虫病患者的临床研究已成功达成最低入组人数这一关键里程碑。这一进展标志着该项目的推进迈出了坚实一步。\n公司同时明确，计划在2026年10月6日之前，对外发布该研究的中期数据解读。这一时间表的设定，为市场及医学界提供了清晰的预期。巴贝斯虫病作为一种罕见且可能危及生命的寄生虫感染，目前有效的治疗选择十分有限，因此这项研究的每一步进展都备受关注。\n围绕此项研究的后续动态，尤其是即将公布的中期数据，投资者和行业观察者都将予以密切关注。这些数据或将为评估相关治疗方案的潜力提供重要依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SXTPW","BK4007","SXTP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172283578","title":"60 Degrees Pharmaceuticals与佛罗里达州立大学达成独家期权协议，共同推进栗精胺用于蜱传疾病治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1172283578","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172283578?lang=zh_cn&edition=full","pubTime":"2026-07-08 20:03","pubTimestamp":1783512208,"startTime":"0","endTime":"0","summary":"60 Degrees Pharmaceuticals 宣布，已与佛罗里达州立大学签署一项独家期权协议，旨在共同推进化合物栗精胺（Castanospermine）用于治疗蜱传疾病的研发工作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SXTPW","SXTP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115356434","title":"60 Degrees Pharmaceuticals宣布数据安全监测委员会对Tafenoquine治疗伴有重度疲劳的慢性巴贝斯虫病患者的B-free二期研究给予积极推荐","url":"https://stock-news.laohu8.com/highlight/detail?id=1115356434","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115356434?lang=zh_cn&edition=full","pubTime":"2026-07-01 20:06","pubTimestamp":1782907607,"startTime":"0","endTime":"0","summary":"60 Degrees Pharmaceuticals宣布，其数据安全监测委员会已对使用Tafenoquine治疗伴有重度疲劳的慢性巴贝斯虫病患者的B-free二期研究给出了积极的推荐意见。这一进展标志着该药物在应对这一特定患者群体需求的研究道路上迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SXTPW","SXTP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159924907","title":"60 Degrees Pharmaceuticals与佛罗里达州立大学签署独家专利许可协议，将澳大利亚栗子提取物作为植物补充剂非处方使用","url":"https://stock-news.laohu8.com/highlight/detail?id=1159924907","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159924907?lang=zh_cn&edition=full","pubTime":"2026-06-11 20:05","pubTimestamp":1781179544,"startTime":"0","endTime":"0","summary":"60 Degrees Pharmaceuticals已与佛罗里达州立大学达成一项独家专利许可协议，旨在将澳大利亚栗子提取物作为植物补充剂进行非处方用途的开发与商业化。该协议标志着公司在其产品管线拓展方面迈出了重要一步，为其在植物补充剂领域的布局提供了关键的技术和知识产权支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SXTP","BK4007","SXTPW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164428215","title":"60 Degrees Pharmaceuticals 宣布首个季节性患者提前入组他非诺喹治疗住院巴贝斯虫病的临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1164428215","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164428215?lang=zh_cn&edition=full","pubTime":"2026-05-26 20:02","pubTimestamp":1779796938,"startTime":"0","endTime":"0","summary":"60 Degrees Pharmaceuticals 宣布，其用于治疗住院巴贝斯虫病患者的他非诺喹临床试验，已提前完成首位季节性患者的入组工作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SXTPW","BK4007","SXTP"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0641},{"period":"1month","weight":0.0691},{"period":"3month","weight":-0.1233},{"period":"6month","weight":-0.4913},{"period":"1year","weight":-0.5084},{"period":"ytd","weight":-0.5812}],"compareEarnings":[{"period":"1week","weight":-0.0059},{"period":"1month","weight":-0.0368},{"period":"3month","weight":-0.0292},{"period":"6month","weight":0.0023},{"period":"1year","weight":0.1005},{"period":"ytd","weight":0.0997}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.006864},{"month":2,"riseRate":0.333333,"avgChangeRate":0.057465},{"month":3,"riseRate":0.666667,"avgChangeRate":0.043011},{"month":4,"riseRate":0.333333,"avgChangeRate":0.468151},{"month":5,"riseRate":0.666667,"avgChangeRate":-0.011035},{"month":6,"riseRate":0,"avgChangeRate":-0.126241},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.258663},{"month":8,"riseRate":0.75,"avgChangeRate":0.50219},{"month":9,"riseRate":0,"avgChangeRate":-0.302565},{"month":10,"riseRate":0.5,"avgChangeRate":-0.128589},{"month":11,"riseRate":0.25,"avgChangeRate":-0.38637},{"month":12,"riseRate":1,"avgChangeRate":0.716052}],"exchange":"NASDAQ","name":"60 Degrees Pharmaceuticals Equity Warrants Exp 16 May 2028 Warrant","nameEN":"60 Degrees Pharmaceuticals Equity Warrants Exp 16 May 2028 Warrant"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"60 Degrees Pharmaceuticals Equity Warrants Exp 16 May 2028 Warrant(SXTPW)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供60 Degrees Pharmaceuticals Equity Warrants Exp 16 May 2028 Warrant(SXTPW)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"60 Degrees Pharmaceuticals Equity Warrants Exp 16 May 2028 Warrant,SXTPW,60 Degrees Pharmaceuticals Equity Warrants Exp 16 May 2028 Warrant股票,60 Degrees Pharmaceuticals Equity Warrants Exp 16 May 2028 Warrant股票老虎,60 Degrees Pharmaceuticals Equity Warrants Exp 16 May 2028 Warrant股票老虎国际,60 Degrees Pharmaceuticals Equity Warrants Exp 16 May 2028 Warrant行情,60 Degrees Pharmaceuticals Equity Warrants Exp 16 May 2028 Warrant股票行情,60 Degrees Pharmaceuticals Equity Warrants Exp 16 May 2028 Warrant股价,60 Degrees Pharmaceuticals Equity Warrants Exp 16 May 2028 Warrant股市,60 Degrees Pharmaceuticals Equity Warrants Exp 16 May 2028 Warrant股票价格,60 Degrees Pharmaceuticals Equity Warrants Exp 16 May 2028 Warrant股票交易,60 Degrees Pharmaceuticals Equity Warrants Exp 16 May 2028 Warrant股票购买,60 Degrees Pharmaceuticals Equity Warrants Exp 16 May 2028 Warrant股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"60 Degrees Pharmaceuticals Equity Warrants Exp 16 May 2028 Warrant(SXTPW)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供60 Degrees Pharmaceuticals Equity Warrants Exp 16 May 2028 Warrant(SXTPW)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}